Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
progression-free survival
period from study inclusion until the date of recurrence or surgery (in case of unresectability at surgical exploration).
from date of randomization until date of progression, assessed up to 5 years
No
Jean-Luc RAOUL, MD
Principal Investigator
Institut Paoli-Calmettes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
NEOPAC / IPC 2011-002
NCT01521702
December 2011
Name | Location |
---|